Close Asset Management Ltd Trims Holdings in Eli Lilly and Company

The institutional investor reduced its stake in the pharmaceutical giant by 3.1% in the third quarter.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Close Asset Management Ltd, an institutional investor, decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 3.1% in the third quarter, according to a recent SEC filing. The firm now owns 57,107 shares of the company's stock, valued at $43.54 million, making it the 26th largest holding in its portfolio.

Why it matters

Eli Lilly is a major pharmaceutical company, and changes in institutional ownership can provide insights into investor sentiment and market trends around the stock. The 3.1% reduction in Close Asset Management's stake, while relatively small, could signal a shift in the firm's outlook on Lilly's prospects.

The details

According to the filing, Close Asset Management sold 1,850 shares of Eli Lilly and Company during the third quarter. The firm now holds a total of 57,107 shares, accounting for approximately 1.0% of its overall portfolio.

  • Close Asset Management filed the 13F report for the third quarter of 2026.

The players

Close Asset Management Ltd

An institutional investor that manages a portfolio of investments, including a position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Close Asset Management's Eli Lilly holdings, while small, could signal a shift in investor sentiment around the pharmaceutical company. However, Eli Lilly remains a significant holding in the firm's portfolio, indicating its continued confidence in the company's long-term prospects.